A groundbreaking study published in Nature reveals how ageing triggers a metabolic shift in cancer cells, unveiling a promising therapeutic vulnerability that could revolutionize treatment strategies for older patients with non-small cell lung cancer (NSCLC). Researchers have identified that metabolic plasticity orchestrated by the transcription factor ATF4 significantly influences metastatic potential, opening new avenues for adjuvant therapies targeting this stress-response pathway.
The investigation centered on comparing two genetically defined cancer cell cultures derived from models of NSCLC: the ATF4-high KP-O and the ATF4-low KP-Y populations. Initial drug screening revealed a surprising specificity in their metabolic dependencies. While both were unresponsive to inhibitors targeting various amino acid transporters and metabolic enzymes such as SLC7A11, BCAT, or PHGDH, KP-O cultures exhibited heightened sensitivity to glutamine deprivation and treatment with DON, a glutamine analogue toxic to cancer cells. This disparity underscores the pivotal role of glutamine metabolism in determining therapeutic responses.
Delving deeper, the focus shifted towards targeting glutaminolysis—the conversion of glutamine to glutamate—central to cellular bioenergetics and biosynthesis. The study employed glutaminase inhibitors (GLSi) CB-839 (telaglenastat) and BPTES, agents capable of halting this rate-limiting step. Remarkably, KP-O cells demonstrated pronounced sensitivity to both drugs, linking high ATF4 expression and glutaminolysis dependency. Additionally, antagonism of ASCT2, the principal glutamine transporter using V-9302, mirrored this effect, further accentuating glutamine’s indispensable role in sustaining KP-O cell viability.
Mechanistic exploration through metabolic rescue experiments painted a nuanced picture of glutamate’s centrality. Pretreatment of KP-O cultures with dimethyl-2-oxoglutarate (DMG), a cell-permeable α-ketoglutarate analog that replenishes critical TCA cycle intermediates, or pyruvate derived from glucose metabolism, effectively reversed sensitivity to CB-839. This rescue was unique as other tested metabolites or antioxidants failed to confer protection, except for erastin, a cysteine–glutamate antiporter system inhibitor. These findings emphatically pinpointed glutamate exhaustion rather than downstream metabolic disruptions as the culprit for GLSi-induced cytotoxicity in KP-O cultures.
Critical to the narrative is the integral role played by ATF4. Genetic ablation or pharmacological attenuation of ATF4 activity using ISRIB (Integrated Stress Response Inhibitor) rendered KP-O cells resistant to CB-839, underscoring the dependency of glutaminase sensitivity on this transcription factor. Conversely, forced ATF4 overexpression in the historically resistant KP-Y cultures conferred newfound vulnerability to GLS inhibition, demonstrating a causal relationship. This interplay also extended to 3D tumor spheroid models: KP-O spheroids lost their characteristic anoikis resistance—a hallmark of metastatic potential—upon GLSi or V-9302 treatment, a defect that was likewise reversed when ATF4 was inhibited.
From a translational perspective, in vivo experiments confirmed the therapeutic promise of targeting glutaminolysis within the metastatic microenvironment. Intravenous transplantation of KP-O cultures into murine hosts resulted in aggressive lung metastasis under vehicle treatment but was nearly abolished with CB-839 administration. Strikingly, KP-Y cells implanted similarly evoked minimal metastatic burden regardless of treatment, demonstrating specificity. Notably, CB-839 did not impede the primary tumor growth in either model following subcutaneous transplantation, a divergence highlighting the metastasis-focused effectiveness of GLS inhibition.
Quantitative assessments endorsed these observations, with CB-839 treatment virtually eradicating distant metastases from KP-O tumors without affecting their primary mass or growth kinetics. This selective suppression of metastatic seeding or outgrowth, sparing tumor proliferation, suggests a unique dependency of metastatic cells on glutaminolysis mediated by ageing and ATF4 activation. These insights may explain the clinical challenges in treating metastasis and underscore the need for tailored metabolic interventions targeting this axis.
This study pioneers the conceptual junction where ageing biology intersects with cancer metabolism and metastasis. The integrated stress response, governed by ATF4, commandeers metabolic rewiring that fosters metastatic competence through glutamine and glutamate utilization. By exploiting this axis using clinically relevant GLS inhibitors, such as CB-839, there appears to be a viable strategy to thwart metastasis specifically in cancers with elevated ATF4 signaling—a phenotype enriched in aged patients.
Future clinical translation of these findings could revolutionize NSCLC management in older demographics, where current therapies exhibit limited efficacy against metastatic disease. It reveals how stress-adaptive transcription factors reshape metabolic landscapes within tumors, creating transient but exploitable vulnerabilities. Moreover, it invites broader applications across cancers exhibiting stress response hyperactivation, potentially heralding a new class of metabolically targeted anti-metastatic agents.
In summary, the novel identification of ageing-induced ATF4-dependent glutamine addiction in metastatic NSCLC cells presents a compelling target for intervention. GLS inhibitors, currently progressing through clinical trials, may find renewed focus as adjuvants to prevent metastatic progression rather than solely tumor reduction. This paradigm shift champions metabolic stress signaling as the Achilles’ heel of metastatic dissemination, reshaping therapeutic paradigms in oncology.
The study’s rigorous integration of cellular, molecular, and in vivo models highlights the precision with which cancer metabolism can be therapeutically manipulated. The metabolic plasticity modulated by ATF4 not only sustains metastasis but unveils a highly selective, context-dependent vulnerability. In doing so, it sets a precedent for unraveling complex age-related oncogenic programs through metabolic intervention, promising enhanced survivorship and quality of life for patients burdened by aggressive lung cancers.
As this research lays the groundwork for targeted metabolic therapies, it also prompts vital questions about long-term effects, resistance mechanisms, and patient stratification. The intersection of ageing biology with cancer therapeutics will undoubtedly continue to burgeon, catalyzing innovative strategies that are as complex and adaptive as the disease they aim to conquer.
Subject of Research: Metabolic rewiring driven by ATF4 in ageing and its impact on metastasis in non-small cell lung cancer.
Article Title: Ageing promotes metastasis via activation of the integrated stress response.
Article References:
Patel, A.A.H., Dzanan, J.J., Ali, K.X. et al. Ageing promotes metastasis via activation of the integrated stress response. Nature (2026). https://doi.org/10.1038/s41586-026-10216-0
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41586-026-10216-0
Tags: adjuvant therapies for NSCLCaging and cancer metastasisATF4 transcription factor rolecancer cell metabolic vulnerabilitiesCB-839 telaglenastat effectsglutaminase inhibitors in therapyglutamine metabolism in cancer cellsglutaminolysis targeting drugsmetabolic plasticity in cancermetabolic shift in cancer cellsnon-small cell lung cancer treatmentstress response pathways in cancer
